Noven Pharmaceuticals Inc. announced that Phase I studies forits transdermal estrogen/progestogen combination deliverysystem are under way.
The studies are being conducted by Rhone-Poulenc Rorer(NYSE:RPR) which has an exclusive worldwide license to theproduct.
Noven (NASDAQ:NOVN) of Miami is applying its adhesive-basedtransdermal drug-delivery technology to hormone replacementtherapy, which is apparently beneficial in controllingmenopausal symptoms, osteoporosis and cardiovascular events.
(c) 1997 American Health Consultants. All rights reserved.